Back to Search Start Over

A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma.

A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma.

Authors :
Encinas C
Hernandez-Rivas JÁ
Oriol A
Rosiñol L
Blanchard MJ
Bellón JM
García-Sanz R
de la Rubia J
de la Guía AL
Jímenez-Ubieto A
Jarque I
Iñigo B
Dourdil V
de Arriba F
Pérez-Ávila CC
Gonzalez Y
Hernández MT
Bargay J
Granell M
Rodríguez-Otero P
Silvent M
Cabrera C
Rios R
Alegre A
Gironella M
Gonzalez MS
Sureda A
Sampol A
Ocio EM
Krsnik I
García A
García-Mateo A
Soler JA
Martín J
Arguiñano JM
Mateos MV
Bladé J
San-Miguel JF
Lahuerta JJ
Martínez-López J
Source :
Blood cancer journal [Blood Cancer J] 2022 Apr 19; Vol. 12 (4), pp. 68. Date of Electronic Publication: 2022 Apr 19.
Publication Year :
2022

Abstract

Infections remain a common complication in patients with multiple myeloma (MM) and are associated with morbidity and mortality. A risk score to predict the probability of early severe infection could help to identify the patients that would benefit from preventive measures. We undertook a post hoc analysis of infections in four clinical trials from the Spanish Myeloma Group, involving a total of 1347 patients (847 transplant candidates). Regarding the GEM2010 > 65 trial, antibiotic prophylaxis was mandatory, so we excluded it from the final analysis. The incidence of severe infection episodes within the first 6 months was 13.8%, and majority of the patients experiencing the first episode before 4 months (11.1%). 1.2% of patients died because of infections within the first 6 months (1% before 4 months). Variables associated with increased risk of severe infection in the first 4 months included serum albumin ≤30 g/L, ECOG > 1, male sex, and non-IgA type MM. A simple risk score with these variables facilitated the identification of three risk groups with different probabilities of severe infection within the first 4 months: low-risk (score 0-2) 8.2%; intermediate-risk (score 3) 19.2%; and high-risk (score 4) 28.3%. Patients with intermediate/high risk could be candidates for prophylactic antibiotic therapies.<br /> (© 2022. The Author(s).)

Details

Language :
English
ISSN :
2044-5385
Volume :
12
Issue :
4
Database :
MEDLINE
Journal :
Blood cancer journal
Publication Type :
Academic Journal
Accession number :
35440057
Full Text :
https://doi.org/10.1038/s41408-022-00652-2